Provided by Tiger Fintech (Singapore) Pte. Ltd.

ASCENTAGE-B

83.600
+0.4500.54%
Volume:5.06M
Turnover:413.73M
Market Cap:31.10B
PE:-57.01
High:83.850
Open:83.850
Low:80.000
Close:83.150
Loading ...

Ascentage Pharma Group International : JP Morgan Raises Target Price to $46 From $27

THOMSON REUTERS
·
Yesterday

HK Movers | Biotech Stocks Extend Rally. Junshi Bio up over 24%; Genor up 23%; Ascletis up 15%; Ascentage up 13%; Dualitybio up 12%

Tiger Newspress
·
05 Aug

Ascentage Pharma to Participate in Evercore China Biotech Summit in Shanghai

Reuters
·
01 Aug

Ascentage Pharma Raises HK$1.5 Billion from Share Sale; Shares Jump 3%

MT Newswires Live
·
28 Jul

Ascentage Pharma Announces Increase in Share Capital: 22 Million New Shares Issued at HK$68.6 Each

Reuters
·
25 Jul

Ascentage Pharma Group International (HKG:6855) Is Expected To Breakeven In The Near Future

Simply Wall St.
·
20 Jul

Ascentage Pharma Group International Completes HKD1.492 Billion Offshore Private Placement to Boost Global Operations

Reuters
·
17 Jul

Hong Kong Stock Movement | Ascentage Pharma (06855.HK) Surges Over 4% in Morning Session After Raising HK$1.5B Via Placement to Accelerate Commercialization and Drug Pipeline Development

Deep News
·
16 Jul

Ascentage Pharma (06855) Gains Over 4% Pre-Market on HK$1.49B Share Placement to Fuel Commercialization and R&D

Stock News
·
16 Jul

Hong Kong Stocks Continue Rally as China's GDP Growth Slows Less Than Expected in Q2; Grand Ming Group Soars on Waivers of Loan Covenants

MT Newswires Live
·
15 Jul

Ascentage Pharma Seeking HK$1.5 Billion via Stock Sale; Shares Fall 6% in Pre-market Trade

MT Newswires Live
·
15 Jul

Ascentage Pharma Group International Announces Placing of Existing Shares and Top-Up Subscription of New Shares

Reuters
·
15 Jul

BRIEF-Ascentage Pharma Group International Prices 22 Mln Shares At HKD 68.60 Each

Reuters
·
14 Jul

Ascentage Pharma Gets China Nod for Lymphocytic Leukemia, Lymphoma Drug

MT Newswires Live
·
10 Jul

Ascentage Pharma's Novel Bcl-2 Inhibitor Lisaftoclax Receives Approval from China's NMPA for Treatment of CLL/SLL Patients

Reuters
·
10 Jul

Ascentage Pharma Group International Announces Key Management Appointments: Dr. Veet Misra as CFO and Eric Huang as SVP of Global Corporate Development and Finance

Reuters
·
08 Jul

Ascentage Pharma Announces New Compensation Plan Under 2021 and 2022 RSU Schemes to Reward and Retain Key Talent

Reuters
·
27 Jun

Ascentage Pharma Unveils Promising Results from Olverembatinib and APG-5918 Clinical Studies at 2025 EHA Congress

Reuters
·
16 Jun

Ascentage Pharma Announces 13 Studies Featuring Olverembatinib and Lisaftoclax at 2025 European Hematology Association Congress

Reuters
·
10 Jun

Ascentage Pharma Group International Announces Regulatory Review for Lisaftoclax in China Following New Drug Application Submission

Reuters
·
23 May